Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

가와사키 병 환아에서 관상동맥 합병증의 예측인자

Predictive indicators of coronary artery complications in Kawasaki disease

  • 박민지 (가천의과학대학교 의학전문대학원) ;
  • 전인상 (가천의과학대학교 소아과학교실) ;
  • 차한 (가천의과학대학교 소아과학교실) ;
  • 조강호 (가천의과학대학교 소아과학교실) ;
  • 정미진 (가천의과학대학교 소아과학교실) ;
  • 최덕영 (가천의과학대학교 소아과학교실)
  • Park, Min Jee (Graduate School of Medicine, Gachon University of Medicine and Science) ;
  • Jeon, In-sang (Department of Pediatrics, Gachon University of Medicine and Science) ;
  • Tchah, Hann (Department of Pediatrics, Gachon University of Medicine and Science) ;
  • Choi, Kang Ho (Department of Pediatrics, Gachon University of Medicine and Science) ;
  • Jung, Mi-Jin (Department of Pediatrics, Gachon University of Medicine and Science) ;
  • Choi, Deok Young (Department of Pediatrics, Gachon University of Medicine and Science)
  • 투고 : 2009.04.06
  • 심사 : 2009.09.02
  • 발행 : 2009.10.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적 : 현재 소아 연령에서 가장 흔한 후천적 심질환의 원인이 되고 있는 가와사키 병은 해마다 발병률이 증가하고 있으며 합병증 발생 또한 증가될 것으로 예상된다. 따라서 가와사키 병 환아의 임상적 소견, 검사실 소견을 바탕으로 가와사키 병의 관상동맥 합병증을 예측할 수 있는 인자를 알아보고자 하였다. 방 법 : 가천의과학대학교 길병원 소아과에서 2005년 1월부터 2008년 3월까지 가와사키 병으로 진단 및 치료를 받은 환아 201명을 대상으로 관상동맥 병변이 없었던 군(group I; 150명)과 있었던 군(group II; 51명)로 나누어 임상적 소견과 검사실 소견을 비교하였고 이 때 선별된 인자들을 바탕으로 관상동맥 병변에 미치는 영향을 도출하였다. 임상적 소견으로는, 나이, 성별, 총 발열기간, IVIG 투여 후 지속된 발열기간, 발열 후 치료 시작되기까지 걸린 기간, IVIG 총 투여횟수, 관상동맥 병변 여부, 검사실 소견으로는, 총 백혈구 수, 중성구 수, 혈색소, 적혈구 용적, 혈소판 수, 혈구침강속도, CRP, 알부민, 총 콜레스테롤, 중성지방 등의 수치가 사용되었다. 결 과 : 두 집단 간의 비교분석에서는, 2군(group II) 이 총 발열기간(P<0.05), IVIG 투여 후 지속된 발열기간(P<0.05), 발열 후 IVIG 치료 시작되기까지 걸린 기간(P<0.05)에서 1군(group I)보다 유의하게 길었다. 치료기간 동안 IVIG 투여 횟수는 1군(group I)이 2군(group II)보다 통계적으로 유의하게 낮은 결과를 보였다(P<0.05). 검사실 소견은 CRP 수치가 2군(group II)에서 의미 있게 높았으나 그 외의 다른 수치들은 양 군 간의 유의한 차이를 보이지 않았다. 앞서 선별된 인자들 중에서, 총 발열기간이 10일 이상일 때, IVIG 투여 후 48시간동안 열이 지속될 때, 발열 후 10일 이상 치료가 지연된 경우에, 각각 약 6배(OR=5.95, P=0.003) 5배(OR=5.11, P=0.005) 3.5배(OR=3.47, P=0.049) 관상동맥 병변 위험이 증가하였다. 또한 IVIG 초 치료보다 IVIG 재 치료(2회 이상)인 경우가 관상동맥 병변 위험이 4배(OR=4.02, P=0.001) 증가하였다. CRP는 6 mg/dL 미만인 집단에 비해 관상동맥 병변 위험이 6-9 mg/dL인 집단에서는 2배(OR=2.32, P=0.049), 9 mg/dL 이상인 집단은 3배(OR=3.18, P=0.003)로 CRP 수치의 증가에 따라 위험도가 증가하는 양상을 보였다. 그러나 위의 다섯 인자를 다변량 분석을 시행하였을 때 의미 있는 위험인자는 IVIG 재 치료(2회 이상) 경우(OR=5.29, P=0.034)와 CRP 6-9 mg/dL (OR=2.63, P=0.040), 9 mg/dL 이상(OR=2.84, P=0.014)만이 확인되었다. 결 론 : 기존 연구와 마찬가지로, 본 연구에서도 발열기간은 관상동맥 병변의 위험도와 가장 관련이 깊은 것으로 나타났으며 가와사키 병의 치료에 있어서 발열 후 IVIG의 신속한 투여로 인해 총 발열기간을 줄이려는 노력의 중요성이 확인되었다. 관상동맥 합병증의 예측인자를 선별하기 위해서는 기존의 알려진 예측인자 간의 연관성을 밝히고 객관화된 평가법의 마련을 위한 추가적인 연구가 더 필요할 것으로 사료된다.

Purpose : Kawasaki disease—the most common cause of acquired heart disease in children—incidence is increasing yearly. Therefore, we evaluated the predictive indicators of coronary complications of Kawasaki disease based on clinical and laboratory data. Methods : Between January 2005 and March 2008, of the 201 children with Kawasaki disease treated at the Gil Hospital of Gachon University of Medicine and Science, 51 had coronary artery lesions (Group II) and 150 had no lesions (Group I). The reasons for coronary artery lesions were deduced from the clinical and laboratory data. Results : Analysis of the 2 groups revealed that fever duration and days of fever after and before initial intravenous gammaglobulin (IVIG) treatment were significantly longer in Group 2 than in Group I. IVIG infusions were statistically higher in Group II than in Group I. As per the laboratory data, C-reactive protein (CRP) value was significantly higher in Group II. Collectively, >10 days of fever duration, >48 h of fever duration after, and >10 days of fever before IVIG treatment increased the risk of coronary artery lesions 6-, 5-, and 3.5-fold, respectively. Furthermore, additional IVIG courses and higher CRP level increased the risk of coronary artery lesions 4-fold and 2-3-fold, respectively. Conclusion : The following 3 factors were responsible for increased risk of coronary artery lesions in children with Kawasaki disease: fever duration and days of fever after and before IVIG treatment. To identifythe predictive indicators of coronary complications, it is necessary to further elucidate the relationship between well-known forecasting factors.

키워드

참고문헌

  1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Jpn J Allergy 1967;16:178-222
  2. Park YW. National survey of Kawasaki disease in Korea. Korean J Pediatr 2007;11:101-5
  3. Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW. A predictive instrument for coronary artery aneurysms in Kawasaki disease. Am J Cardiol 1998;81:1116-20 https://doi.org/10.1016/S0002-9149(98)00116-7
  4. Honkanen VE, McCrindle BW, Laxer RM, Feldman BM, Schneder R, Silverman ED. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Pediatr Cardiol 2003;24:122-6 https://doi.org/10.1007/s00246-002-0063-1
  5. Gersony WM. Predicting coronary aneurysms in Kawasaki disease. Am J Cardiol 1998;81:1162-4 https://doi.org/10.1016/S0002-9149(98)00115-5
  6. Koyanagi H, Yanagawa H, Nakamura Y, Yashiro M. Leukocyte counts in patients with Kawasaki disease: from the results of nationwide surveys of Kawasaki disease in Japan. Acta Paediatr 1997;86:1328-32 https://doi.org/10.1111/j.1651-2227.1997.tb14907.x
  7. Dajani AS, Taubert KA, Gerber MA, Shilman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80 https://doi.org/10.1161/01.CIR.87.5.1776
  8. Fukushige J, Takahashi N, Ueda K. Incidence and clinical features of incomplete Kawasaki disease. Acta Paediatr 1994; 83:1057-60 https://doi.org/10.1111/j.1651-2227.1994.tb12985.x
  9. Research Committee on Kawasaki Disease. Report from subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan: Ministry of Health and Welfare; 1984
  10. Oh IJ, Moon KH, Hong ME, Kim YS, Lee CW. Clinical significance of follow-up laboratory tests, performed at 6 weeks after the onset of Kawasaki disease. Korean J Pediatr 2006; 49:672-6 https://doi.org/10.3345/kjp.2006.49.6.672
  11. Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada Y, et al. Coronary risk factors in Kawasaki disease treated with additional gamma globulin. Arch Dis Child 2004; 89:776-80 https://doi.org/10.1136/adc.2003.032748
  12. Kim SE, Oh JH, Park SH, Koh DK. Coronary complication according to retreatment of immune globulin in Kawasaki disease. J Korean Pediatr Heart Asso 2007;3:124-30
  13. Koren G, Lavi S, Rosa V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986;108: 388-92 https://doi.org/10.1016/S0022-3476(86)80878-2
  14. Newburger JW, Takahashi M, Burns JC, Beiser AC, Chung KJ, Duffy CF, et al. Treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-47 https://doi.org/10.1056/NEJM198608073150601
  15. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. Single infusion of intravenous gamma globulin compared to four daily doses in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-39 https://doi.org/10.1056/NEJM199106063242305
  16. Harada K. Intravenous gamma-globulin treatment for Kawasaki disease. Acta Paediatr Jpn 1991;33:805-10 https://doi.org/10.1111/j.1442-200X.1991.tb02612.x
  17. Anderson MS, Burns J, Treadwell TA, Pietra BA, Glode MP. Erythrocyte sedimentation rate and C-reactive protein discrepancy and high prevalence of coronary artery abnormalities in Kawasaki disease. Pediatr Infect Dis J 2001;20:698-702 https://doi.org/10.1097/00006454-200107000-00011
  18. Choi BY, Oh JH, LEE SJ, Han JW, Koh DK, Oh CK. Comparison of intervals to peak values of laboratory findings in patients with coronary complication to those without complication in Kawasaki disease. J Korean Pediatr Heart Asso 2005;9:357-64
  19. Seo SY, Oh JH, Kim JH, Han JW, Lee KY, Koh DK. Giant coronary and axillary aneurysms in an infant with Kawasaki disease associated with thrombocytopenia. Korean J Pediatr 2005;48:901-6
  20. Ichida F, Fatica NS, Engle MA, O'Loughlin JE, Klein AA, Snyder MS, et al. Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk factors and role of aspirin. Pediatrics 1987;80:828-35
  21. Eberhard BA, Andersson U, Laxer RM, Rose V, Silverman ED. Evaluation of the cytokine reponse in Kawasaki disease. Pediatr Infect Dis J 1995;14:199-203 https://doi.org/10.1097/00006454-199503000-00006
  22. Furukawa S, Matsubara T, Yone K, Ilirano Y, Okumura K, Yabuta K. Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumor necrosis factor-alpha and interleukin 6 in serum. Eur J Pediatr 1992;151:44-7 https://doi.org/10.1007/BF02073890
  23. Ishiguro A, Ishikita T, Shimbo T, Matsubara K, Baba K, Hayashi Y, et al. Elevation of serum thrombopoietin precedes thrombocytosis in Kawasaki disease. Thromb Haemost 1998; 79:1096-100 https://doi.org/10.1055/s-0037-1615022

피인용 문헌

  1. N-terminal Pro-Brain Natriuretic Peptide (NT proBNP) as a Predictive Indicator of Initial Intravenous Immunoglobulin Treatment Failure in Children With Kawasaki Disease: A Retrospective Study vol.34, pp.8, 2009, https://doi.org/10.1007/s00246-013-0724-2
  2. Non-Responders to Intravenous Immunoglobulin and Coronary Artery Dilatation in Kawasaki Disease: Predictive Parameters in Korean Children vol.46, pp.4, 2009, https://doi.org/10.4070/kcj.2016.46.4.542
  3. Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose “IVIG-SN” Therapy for Pediatric Patients with Kawasaki Disease vol.47, pp.2, 2009, https://doi.org/10.4070/kcj.2016.0139